Efficacy and Safety of Resveratrol and Carbossimetyl Beta Glucan in Treatment of Upper Airways Disease in Infancy
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
outpatient infants (0-6 months of life), affected by symptoms of upper airways disease will
be randomly assigned to two type of intervention:
A: treatment group, receiving resveratrol and carbossimetyl beta glucan; B: control group,
receiving saline solution.
Each subject underwent clinical history, objective examination and detection of rinovirus in
the nasal secretions at enrollment, after 48 hours and after 7 and 30 days.